Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.57 |
| ▸ | KMO | O15229 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.40 |
| ▸ | HTR2A | P28223 | 11/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.39 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21820786 | 0.86 | HSP90AA1 (0.71) | HSP90AA1KMOMEN1KMT2AHAO1 | |
| SCHEMBL3294395 | 0.82 | KMO (0.56) | HSP90AA1KMOMEN1KMT2AHAO1 | |
| SCHEMBL10614755 | 0.80 | KMO (0.62) | HSP90AA1KMOMEN1KMT2AHAO1 | |
| SCHEMBL5540628 | 0.79 | SLC6A4 (0.40) | HSP90AA1MEN1KMT2ASLC6A4HTR2A | |
| SCHEMBL10354980 | 0.78 | HSP90AA1 (0.74) | HSP90AA1KMOMEN1KMT2AHAO1 | |
| SCHEMBL10354976 | 0.78 | HSP90AA1 (0.57) | HSP90AA1KMOMEN1KMT2AHAO1 | |
| SCHEMBL11175966 | 0.78 | HSP90AA1 (0.57) | HSP90AA1KMOMEN1KMT2AHAO1 | |
| SCHEMBL632533 | 0.78 | MAOA (0.61) | HSP90AA1KMOMEN1KMT2ASLC6A4 | |
| SCHEMBL12260895 | 0.78 | HSP90AA1 (0.57) | HSP90AA1KMOMEN1KMT2AHAO1 | |
| SCHEMBL257844 | 0.78 | HSP90AA1 (0.57) | HSP90AA1KMOMEN1KMT2AHAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6699836-B2 | Vancomycin analogs | THE TRUSTEES OF PRINCETON UNIVERSITY | 2004-03-02 | — | — | US | claimed |
| US-20020042365-A1 | Vancomycin analogs | TRUSTEES OF PRINCETON UNIVERSITY, THE | 2002-04-11 | — | — | US | claimed |
| WO-2001081372-A2 | VANCOMYCIN ANALOGS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2001-11-01 | — | — | WO | claimed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-6841661-B2 | Glycopeptide antibacterial compounds, compositions containing same and methods of using same | PRINCETON UNIVERISITY (US) | 2005-01-11 | — | — | US | disclosed |
| US-20040110665-A1 | Desleucyl glycopeptide antibiotics and methods of making same | KAHNE DANIEL (US) | 2004-06-10 | — | — | US | disclosed |
| US-6699836-B2 | Vancomycin analogs | THE TRUSTEES OF PRINCETON UNIVERSITY | 2004-03-02 | — | — | US | disclosed |
| EP-0667353-B1 | Glycopeptide antibiotic derivatives | LILLY CO ELI (US) | 2003-10-29 | — | — | EP | disclosed |
| EP-1016670-B1 | Glycopeptide antibiotic derivatives | LILLY CO ELI (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6518243-B1 | Desleucyl glycopeptide antibiotics and methods of making same | TRUSTEES OF PRINCETON UNIVERSITY | 2003-02-11 | — | — | US | disclosed |
| US-6498238-B1 | Glycopeptide antibacterial compounds, compositions containing same and methods of using same | PRINCETON UNIVERSITY | 2002-12-24 | — | — | US | disclosed |
| US-20020042365-A1 | Vancomycin analogs | TRUSTEES OF PRINCETON UNIVERSITY, THE | 2002-04-11 | — | — | US | disclosed |
| WO-2001081372-A2 | VANCOMYCIN ANALOGS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2001-11-01 | — | — | WO | disclosed |
| EP-1016670-A1 | Glycopeptide antibiotic derivatives | ELI LILLY AND COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| US-5977062-A | ACTIVE AGAINST ANTIBIOTIC RESISTANT BACTERIA | ELI LILLY AND COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110665-A1 | Desleucyl glycopeptide antibiotics and methods of making same | FUT6, FUT5, ST6GAL1 | HSP90AA1 1714/4885KMO 2191/4885MEN1 1692/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | HSP90AA1 2576/4885KMO 3391/4885MEN1 4525/4885 |
| US-20020042365-A1 | Vancomycin analogs | VNN1, PTMS, ASNS | HSP90AA1 1321/4885KMO 2678/4885MEN1 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.